AVR (ASX) EGM update

Originally posted by dgoynich ↑

I'll start by saying I've already voted Yes to all and imo the only sane thing you can do if you want the business the thrive rather than just survive...or worse...

When WP took over and attracted medtech professionals to the board - ditching the old mining crew, he could see the potential of adapt.

At the time, Admedus didn't have Scott bliss the ex Baxter engineer and they also didnt quite understand what they could do with cardiocel and the adapt tissue but they new it was special.

The road map wasn't that great and was filled with flat tissue products with the standout being stem cells.

If you could see the top secret road map today (I have) you'd realise the flat patches are yesterday's news. 3d was just a tester and proof of concept. The new road map is filled with unique high margin high profitability products.

3d precipitated and helped bring to life TAVR but it ain't cheap. We have an advisory board which does cost money BUT is fast tracking delivery and has improved vastly in the original concept to the point whereby one of the leading surgeons on the advisory board who helped another firm develop their leading Tavr stated we are miles in front already. That's a multibillion dollar yearly revenue stream we can enter and take over... if we have the cash to finish the job!

Now... recent communications with Wayne... he stated we have a few other catheter based projects aside from TAVR. TAVR is not the only one.
Heck 3d is not our only 3d tissue product and it certainly isn't the largest market... But we need cash to develop more.

The shaped portfolio is unique in that it allows AHZ to develop shaped products that target specific types of surgery and make it much quicker to perform as adapt doesn't require washing (up to 45mins time saving in the theater); and fits the specific need with being cut or folded or kinked inside the patient.

In each one of these cases there is the opportunity to displace all serious competitors. One by one we take their market and destroy their market share.

And we do this without calcification or rejection of the tissue.

BUT... we can't develop these products without cash. It takes money to engineer, gain approval, test in animals and patients.

It doesn't take infinite amounts of cash but more than we had.

So by voting no and imo you are potentially killing your own golden goose. It's got NOTHING to do with dilution- it's got nothing to do with lotto. It's got to do with return on investment.

A different counter example to lotto would be investing in a mining company whereby you continually get diluted but the resource in the ground isn't growing. It's a finite resource so every dilution minimises your share of that resource.

With AHZ the potential resource is continually getting bigger by providing the funds to grow a portfolio. If what WP is saying is true, then the very real outcome and potential is that even if you don't contribute to a CR, you can still significantly more than benefit by allowing a CR to proceed.

So I understand if one personally does not want to contribute to a "potential" further cr... But don't cut off your nose despite your face and don't destroy your golden goose. I expect WP and the board to fully pursue ANY and ALL realistic opportunities... sadly we are hamstrung by lack of cash and limiting our own growth.

So I think voting no is incredibly short sighted given the potential and I've seen no structured counter argument from anyone.

gltah and dyor
Cheers
David

Expand

“When WP took over and attracted medtech professionals to the board”.
If my memory serves right they are all pharma not medtech guys except very recent one and that was the first blunder WP did by appointing all pharma guys.

No.	Vol.	Price($)
1	286	$9.80

No.

Vol.

Price($)

286

$9.80

Price($)	Vol.	No.
$10.99	198	1

Price($)

Vol.

No.

$10.99

198

No.	Vol.	Price($)
1	286	9.800
1	200	9.600
1	2	9.540
1	200	9.500
1	53	9.450

No.

Vol.

Price($)

286

9.800

200

9.600

9.540

200

9.500

9.450

Price($)	Vol.	No.
10.990	198	1
11.500	250	1
12.000	5000	1
12.500	560	1
13.000	2000	1

Price($)

Vol.

No.

10.990

198

11.500

250

12.000

5000

12.500

560

13.000

2000

(20min delay)
Last $10.00		Change 0.000(0.00%)		Mkt cap ! $211.3M

Open	High	Low	Value	Volume
$10.00	$10.00	$9.80	$96.66K	9.794K

EGM update, page-24

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump is President Again: What Does This Mean for Crypto?

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Nanocap Pure Resources acquires Reedy Creek garnet project, WA

Prospech finds dynamite heavy REE grades from historic core in Finland

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

EGM update, page-24

Top Stories

The ASX can overlook its Telecomm small-caps. Here’s one diversified brand with an international footprint

Trump is President Again: What Does This Mean for Crypto?

To make modern missiles, you need 3D Printing. And in that gold rush, Amaero is selling shovels

Nanocap Pure Resources acquires Reedy Creek garnet project, WA

Prospech finds dynamite heavy REE grades from historic core in Finland

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News